JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feeley, K M
Right arrow Articles by Wells, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feeley, K M
Right arrow Articles by Wells, M
J Clin Pathol 2001; 54:435-440
© 2001 Journal of Clinical Pathology


Leader

Hormone replacement therapy and the endometrium

K M Feeley1, M Wells2

1 Department of Histopathology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
2 Section of Oncology and Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Sheffield S10 2RX, UK

Professor Wells m.wells{at}sheffield.ac.uk Modern hormone replacement therapy (HRT) regimens contain oestrogen and progestogen, given either in a cyclical or continuous combined manner. Most endometrial biopsies from women on sequential HRT show weak secretory features. Approximately 15% show proliferative activity, although this figure may be less if more than nine days of progestogen is given in each cycle. A small proportion will show an inactive or atrophic endometrium. Up to 50% of biopsies from women on continuous combined HRT contain minimal endometrial tissue for histopathological analysis: this correlates well with an atrophic endometrium with no appreciable pathology. Of the 50% with more substantial material, approximately one half will show endometrial atrophy, and one half will show weak secretory features. Proliferative, menstrual, and pseudodecidual changes are rare. Approximately 20% of women given unopposed oestrogen for one year develop endometrial hyperplasia. The relative risk of endometrial carcinoma is two to three. This is dramatically reduced by the addition of progestogen to the regimen, but cyclical progestogen as part of a sequential HRT regimen does not completely eliminate the risk of carcinoma. The prevalence of endometrial hyperplasia associated with sequential HRT is 5.4%, and that of atypical hyperplasia (endometrial intraepithelial neoplasia) is 0.7%. Continuous combined HRT is not associated with the development of hyperplasia or carcinoma, and may normalise the endometrium of women who have developed complex hyperplasia on sequential HRT. The probability of a histopathologist finding clinically relevant pathology in an endometrial biopsy specimen of a patient on HRT is low and is more likely to be a manifestation of pre-existing disease.

Key Words: endometrium • hormone replacement therapy • endometrial hyperplasia • endometrial carcinoma




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
H. Zang, L. Sahlin, B. Masironi, E. Eriksson, and A. Linden Hirschberg
Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2169 - 2175.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
W G McCluggage
My approach to the interpretation of endometrial biopsies and curettings.
J. Clin. Pathol., August 1, 2006; 59(8): 801 - 812.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J Christoffel, G Rimoldi, and W Wuttke
Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment.
J. Endocrinol., March 1, 2006; 188(3): 397 - 405.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. W.S. Chan, K. E. Schwab, and C. E. Gargett
Clonogenicity of Human Endometrial Epithelial and Stromal Cells
Biol Reprod, June 1, 2004; 70(6): 1738 - 1750.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. Blok, P. E. De Ruiter, E. C. M. Kuhne, E. E. Hanekamp, J. A. Grootegoed, E. Smid-Koopman, S. C. J. P. Gielen, M. E. De Gooyer, H. J. Kloosterboer, and C. W. Burger
Progestagenic Effects of Tibolone on Human Endometrial Cancer Cells
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2327 - 2334.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.